

Friday 11 March 2011

	Pearl A	Pearl D	Azzurea
14:30	<p>31. CRT: HOW TO AVOID NON-RESPONDERS? Co-chairmen: Zahid Aslam (Pakistan) – Philippe Ritter (France)</p> <p>Tips and tricks in CRT implantation Ahmed Al Fagih (KSA)</p> <p>Benefit of quadripolar LV lead Ali Sayegh (Kuwait)</p> <p>Interventricular delay: Does it make a difference? Maurice Khoury (Lebanon)</p> <p>Two CS leads: when and How? TBA</p> <p>Different techniques for LV lead placement Antonio Curnis (Italy)</p> <p>Made possible thanks to a grant from St Jude medical</p>	<p>32. SELECTION OF PATIENTS FOR CRT AND ICD BEYOND EJECTION FRACTION Co-chairmen: Abdo Daou (Lebanon) – Christian Wolpert (Germany)</p> <p>Current European guidelines for implanted devices Christian Wolpert (Germany)</p> <p>Other parameter than EF, and management of patients not included in the clinical trials? Luc Jordaens (The Netherlands)</p> <p>Should the guidelines be changed after recent clinical trials? Michel Chauvin (France)</p> <p>Can genetic testing help for selecting patients for ICD's Carlo Napolitano (Italy)</p>	<p>33. FIGHTING THE RISKS OF STROKE: HYPERTENSION AND ATRIAL FIBRILLATION Co-chairmen: Samir Arnaout (Lebanon) – Elie Chammas (Lebanon)</p> <p>Microalbuminuria and the risk of CVD: Benefit of combining CCB and ACEI Joseph Galceran (Spain)</p> <p>Hypertension and stroke: Is atrial fibrillation behind? Jean-Yves Le Heuzey (France)</p> <p>Efficacy of propafenone in the management of AF Maurice Khoury (Lebanon)</p> <p>Evidence-based approach to secondary prevention of stroke Atul Pathak (France)</p> <p>Made possible thanks to a grant from Abbott</p>
16:00	<p>COFFEE BREAK</p>	<p>COFFEE BREAK</p>	<p>COFFEE BREAK</p>
16:30	<p>34. WHAT'S NEW IN THE MANAGEMENT OF AF Co-chairmen: Luc Jordaens (The Netherlands) – Antonio Raviolo (Italy)</p> <p>New classification of AF: a structural-based classification Lessons from MRI Nassir Marrouche (USA)</p> <p>Are new antiarrhythmic drugs real novelties? Jean-Yves Le Heuzey (France)</p> <p>Hybrid therapy for AF ablation Claudio Muneretto (Italy)</p> <p>What's new in the new guidelines Alexandre Kharma (Lebanon)</p>	<p>35. VENTRICULAR ARRHYTHMIAS, SUDDEN CARDIAC DEATH IN SPECIAL POPULATIONS: MECHANISM AND MANAGEMENT Co-chairmen: Omar Al Hage (UAE) – Samer Nasr (Lebanon)</p> <p>Management of VT in patient with implanted devices: how to avoid appropriate and inappropriate shocks Fred Abi Samra (USA)</p> <p>In patients with Hypertrophic cardiomyopathy Christian Wolpert (Germany)</p> <p>In patients with CAD and ejection fraction >35% Michel Chauvin (France)</p> <p>Sudden Death Prevention early after an acute MI: The benefit of Omega3 fatty acids Massimo Santini (Italy)</p>	<p>36. DRUGS AFFECTING LIPID METABOLISM: UPDATE (Joint with the Lebanese Atherosclerosis Society) Co-chairmen: Sélim Jambart (Lebanon) – Jaber Sawaya (Lebanon)</p> <p>Insight the lipid pathway Sélim Jambart (Lebanon)</p> <p>When low LDL cholesterol is not reached Leslie Cho (USA)</p> <p>When low LDL cholesterol is not enough Walter Riesen (Switzerland)</p> <p>INTERACTIVE SESSION with the compliments of MSD</p>
18:30	<p>BREAK</p>		
18:45	<p>37. DEBATE ON COMBINATION THERAPY IN HYPERTENSION Co-chairmen: Jose Khabouth (Lebanon)</p> <p>1. Combination therapy should be given to all hypertensive patients: Pro: Roland Asmar (France) Con's: Bernard Waeber (Switzerland)</p>		
20:00	<p>A Boehringer – Ingelheim Symposium</p>		